Welcome to our dedicated page for IGC Pharma news (Ticker: IGC), a resource for investors and traders seeking the latest updates and insights on IGC Pharma stock.
IGC Pharma, Inc. develops therapeutics for Alzheimer's disease and metabolic disorders as a clinical-stage biotechnology company. News about IGC Pharma commonly centers on IGC-AD1, its cannabinoid-based lead asset in the CALMA Phase 2 trial for agitation in Alzheimer's dementia, along with pipeline programs such as TGR-63, IGC-1C and IGC-M3 targeting amyloid plaques, tau pathways, neuroinflammation and related neurodegeneration biology.
Company updates also cover the use of artificial intelligence in drug discovery and clinical-trial operations, including the Agentic Harmonization Assistant platform for biomedical data harmonization. Other recurring developments include clinical-site expansion, caregiver and patient-engagement initiatives, psilocybin research authorization in Colombia, patent activity and financial reporting.
IGC Pharma (NYSE American:IGC) has announced promising preclinical data for its investigational molecule IGC-M3 in the treatment of Alzheimer's disease. The in vitro studies demonstrate that IGC-M3 targets multiple biological mechanisms central to Alzheimer's pathology through four key actions:
The compound has shown ability to inhibit amyloid aggregation, promote disassembly of amyloid aggregates, neutralize reactive oxygen species, and reduce pro-inflammatory signaling in cellular models. In SH-SY5Y human neuronal cells, IGC-M3 demonstrated neuroprotective effects, while in BV2 microglial cells, it reduced Aβ42-induced activation and decreased pro-inflammatory markers.
The company plans to advance IGC-M3 to in vivo studies to evaluate its potential efficacy and safety in animal models, aiming to develop a disease-modifying treatment for Alzheimer's.
IGC Pharma (NYSE American: IGC) announced it will present three scientific posters at the 2025 Alzheimer's Association International Conference (AAIC) in Toronto from July 27-31, 2025. The presentations will showcase the company's AI-driven innovations in Alzheimer's disease research.
The posters will highlight: 1) MINT-AD, an AI foundation model trained on 100+ global datasets for Alzheimer's risk assessment, 2) Research on using large language models to predict cognitive scores without brain scans or blood biomarkers, and 3) An AI-powered drug discovery pipeline focusing on GLP-1 and CB1 targets for Alzheimer's treatment.
IGC Pharma (NYSE American:IGC), a clinical-stage biopharmaceutical company focused on Alzheimer's disease, announced that its Principal Scientist, Dr. Jagadeesh Rao, has received the Best Researcher Award at the 11th Annual World Neuroscientist Awards. The recognition comes from an international panel of experts, highlighting his 15+ years of scientific leadership in neuroscience research.
Dr. Rao's work has been crucial in advancing IGC-AD1, the company's investigational drug currently in Phase 2 trials for treating agitation in Alzheimer's patients. His selection came from a competitive pool of over 360 nominations across 125 countries.
IGC Pharma (NYSE American:IGC) has unveiled MINT-AD, an AI-powered diagnostic platform designed to identify individuals at high risk of Alzheimer's disease before symptoms manifest. The Multimodal Interpretable Transformer for Alzheimer's platform integrates diverse data sources including brain scans, genetics, lifestyle, and cognitive metrics to generate risk profiles and cognitive decline forecasts.
The company plans to launch a beta version in Fiscal 2026 for pilot evaluation with academic and clinical partners. MINT-AD aims to address the global diagnostic gap, where over 400 million people may have Alzheimer's-related pathology before clinical symptoms appear. The platform is designed to extend cognitive diagnostics beyond specialized facilities to general practices and underserved populations.
IGC Pharma (NYSE American: IGC) has released its Fiscal Year 2025 financial results and operational highlights, marking significant progress in its Alzheimer's disease research and development programs. The company's lead asset, IGC-AD1, demonstrated positive interim results in its Phase 2 CALMA trial, showing significant reduction in agitation and sleep disturbances in Alzheimer's patients.
Financial results show revenue of $1.2 million in FY2025, slightly down from $1.3 million in FY2024. The company reduced its net loss to $7.1 million ($0.09 per share) from $13 million ($0.22 per share) in FY2024. SG&A expenses decreased by 35% to $4.4 million, while R&D expenses were $3.7 million. The company raised $4.64 million through equity placements and ATM offerings.
Key operational achievements include expanding clinical trial sites across North America, advancing the development of MINT-AD (an AI-based diagnostic tool), and winning two PREPARE Challenge awards. The company plans to complete the CALMA Phase 2 trial, launch a second Phase 2 study for IGC-AD1's disease-modifying effects, and deploy a beta version of MINT-AD in FY2026.
IGC Pharma (NYSE American:IGC) has scheduled a conference call and webcast for Monday, June 30, 2025, at 11:00 a.m. ET to discuss their fiscal year 2025 operational progress and financial results for the period ended March 31, 2025. The financial results will be released before market opening on the same day.
Shareholders and investors can participate via phone by dialing (888) 506 0062 (US) or (973) 528 0011 (International) using access code 370284. A webcast will be available, and a replay can be accessed until July 31, 2025.
IGC Pharma (NYSE:IGC) has announced a new clinical trial site at Santa Cruz Behavioral (SCB) in Puerto Rico for its CALMA Phase 2 clinical trial, which is investigating IGC-AD1 for agitation in Alzheimer's disease. The strategic location addresses a significant market need, as Puerto Rico has a 12.5% Alzheimer's prevalence rate among those over 65, higher than the 10% rate in non-Hispanic white populations in the U.S.
The selection of Puerto Rico is particularly significant due to its rapidly aging demographic and unique genetic predispositions. Dementia-related medical care in Puerto Rico accounts for over 25% of total societal healthcare costs, exceeding proportions in the continental U.S. This new site complements IGC's existing trial location at the University of Puerto Rico.
IGC Pharma (NYSE American: IGC) presented key genetic toxicology safety data for one of the active pharmaceutical ingredients (APIs) in IGC-AD1, its investigational Alzheimer's disease drug, at the 2025 Genetic Toxicology Association Annual Meeting. The study, conducted by an independent Canadian lab, evaluated melatonin's mutagenic potential using the Bacterial Reverse Mutation Test (Ames test).
The GLP-compliant study tested multiple bacterial strains at concentrations from 1.6 to 5000 µg/plate. Results showed no evidence of mutagenicity at any dose level, with Fold Response values remaining below the mutagenic activity threshold. This safety milestone supports IGC-AD1's development as the company prepares for larger trials and potential commercialization.
IGC Pharma (NYSE American:IGC) announced that its recently appointed advisors have entered into a Share Purchase Agreement on April 21, 2025, to invest approximately $475,000 in the company. The investment price is set at the higher of 30 cents or $0.01 over the last closing price.
Under the agreement, IGC will issue 1,583,333 shares of unregistered common stock, subject to 144 restrictions and a six-month trading lockup period. The private placement completion requires NYSE approval and other customary closing conditions.
The funds will support general corporate purposes and advance IGC's CALMA Phase 2 clinical trial focusing on agitation in Alzheimer's disease. The company views this investment as a vote of confidence from its advisors in IGC's mission to transform Alzheimer's treatment.